Search Result

Isoforms Recommended:	VEGFR1/Flt-1

Results for "

VEGFR1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (5) Aurora Kinase (1) Autophagy (16) Bcl-2 Family (1) c-Fms (5) c-Kit (34) c-Met/HGFR (2) Caspase (1) Checkpoint Kinase (Chk) (1) Complement System (1) Discoidin Domain Receptor (2) Drug Metabolite (9) EGFR (2) ERK (1) FGFR (41) FLT3 (9) Isotope-Labeled Compounds (8) MEK (1) Necroptosis (1) NO Synthase (2) PD-1/PD-L1 (1) PDGFR (52) PKA (1) PKC (3) Raf (8) RET (15) RIP kinase (1) Src (5) Syk (1) Tie (5) Trk Receptor (2) VEGFR (82)
By Research Areas:	Cancer (93) Cardiovascular Disease (4) Inflammation/Immunology (5) Metabolic Disease (2)

By Targets:

Akt (2)

Apoptosis (5)

Aurora Kinase (1)

Autophagy (16)

Bcl-2 Family (1)

c-Fms (5)

c-Kit (34)

c-Met/HGFR (2)

Caspase (1)

Checkpoint Kinase (Chk) (1)

Complement System (1)

Discoidin Domain Receptor (2)

Drug Metabolite (9)

EGFR (2)

ERK (1)

FGFR (41)

FLT3 (9)

Isotope-Labeled Compounds (8)

MEK (1)

Necroptosis (1)

NO Synthase (2)

PD-1/PD-L1 (1)

PDGFR (52)

PKA (1)

PKC (3)

Raf (8)

RET (15)

RIP kinase (1)

Src (5)

Syk (1)

Tie (5)

Trk Receptor (2)

VEGFR (82)

By Research Areas:

Cancer (93)

Cardiovascular Disease (4)

Inflammation/Immunology (5)

Metabolic Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR	Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human *Anti-VEGFR-1* IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors ^[1].

AAL993	VEGFR	Cardiovascular Disease Cancer
IC₅₀s of 130 nM, 23 nM, and 18 nM for VEGFR1, VEGFR2, and VEGFR3, respectively. AAL993 shows less potently inhibits other tyrosine kinases. AAL993 possesses potent antiangiogenic and antitumor properties ^[1].

(Z)-FeCP-oxindole	VEGFR	Cancer
(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC₅₀ value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC₅₀ less than 1 μM ^[1].

KRN-633 3 Publications Verification	VEGFR	Cancer
KRN-633 is a potent *VEGFR* inhibitor with IC₅₀s of 170, 160 and 125 nM for VEGFR1, VEGFR2 and VEGFR3, respectively.

Chiauranib Ibcasertib; CS2164	VEGFR PDGFR c-Kit Aurora Kinase c-Fms	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, *VEGFR2, VEGFR3, PDGFRα* and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase *CSF-1R, with IC₅₀* values ranging from 1-9 nM. Chiauranib has strongly anticancer effects ^[1].

Brivanib 3 Publications Verification BMS-540215	VEGFR Autophagy	Cancer
Brivanib (BMS-540215) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β ^[1].

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for *VEGFR2/VEGFR1, MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively ^[1] .

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for *VEGFR2, VEGFR1, PDGFRβ* and KIT.

(E)-FeCP-oxindole	VEGFR	Cancer
(Z)-FeCP-oxindole is a selective human vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with an IC₅₀ value of 200 nM. (Z)-FeCP-oxindole can significantly inhibit VEGFR1 and PDGFRa or b at 10 μM. (Z)-FeCP-oxindole has some anticancer activity, acting on B16 murine melanoma lines with IC₅₀ less than 1 μM ^[1].

Dovitinib lactate hydrate TKI258 lactate hydrate; CHIR-258 lactate hydrate	FLT3 c-Kit FGFR VEGFR PDGFR	Cancer
Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, *FGFR1/3, VEGFR1/2/3* and PDGFRα/β, respectively ^[1].

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for *VEGFR2, VEGFR1, PDGFRβ* and KIT.

Brivanib (alaninate) 3 Publications Verification BMS-582664	VEGFR Autophagy	Cancer
Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

Tivozanib 5+ Cited Publications AV-951; KRN951	VEGFR	Cancer
Tivozanib (AV-951; KRN951) is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib exhibits antitumor efficacy ^[1].

EG00229 trifluoroacetate 5+ Cited Publications	Complement System	Cancer
EG00229 is a neuropilin 1 (NRP1) receptor antagonist. EG00229 selectively inhibits VEGF-A binding to *NRP1* b1 domain with an IC₅₀ of 3 μM, but has no effect on VEGFA binding to VEGFR-1 and VEGFR-2 ^[1].

Tivozanib hydrochloride hydrate 5+ Cited Publications AV-951 hydrochloride hydrate; KRN951 hydrochloride hydrate	VEGFR	Cancer
Tivozanib hydrochloride hydrate is the hydrate hydrochloride form of Tivozanib (HY-10977). Tivozanib hydrochloride hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrochloride hydrate exhibits antitumor efficacy ^[1].

Sulfatinib 2 Publications Verification Surufatinib; HMPL-012	FGFR VEGFR	Cancer
Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against *VEGFR1/2/3, FGFR1* and *CSF1R* with IC₅₀s of in a range of 1 to 24 nM.

NVP-ACC789 ACC-789; ZK202650	VEGFR PDGFR	Cancer
NVP-ACC789 is an inhibitor of human *VEGFR-1, VEGFR-2* (mouse *VEGFR-2), VEGFR-3* and PDGFR-β with IC₅₀s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively.

BPTQ	VEGFR Checkpoint Kinase (Chk) Apoptosis Caspase Bcl-2 Family	Cancer
BPTQ is a potent inhibitor against *VEGFR1* and CHK2 with IC₅₀ values of 0.54 and 1.70 µmol/L, respectively. BPTQ is also an intercalator of DNA with anticancer activities. BPTQ inhibits the proliferation of HL-60 cells by arresting cells at S and G2/M phase with an IC₅₀ value of 12 µmol/L. BPTQ also activates the mitochondria-mediated Apoptosis pathway by a decrease in mitochondrial membrane potential, increase in the Bax:Bcl-2 ratio and activation of caspases ^[1] .

Lenvatinib 50+ Cited Publications E7080	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

Lenvatinib mesylate 50+ Cited Publications E7080 mesylate	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

Axitinib 25+ Cited Publications AG-013736	VEGFR PDGFR	Cancer
Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

Brivanib (Standard)	VEGFR Autophagy	Cancer
Brivanib (Standard) is the analytical standard of Brivanib. This product is intended for research and analytical applications. Brivanib (BMS-540215) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM, and has moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β ^[1].

Tivozanib hydrate 5+ Cited Publications AV-951 hydrate; KRN951 hydrate	VEGFR	Cancer
Tivozanib hydrate (AV-951 hydrate; KRN951 hydrate) is the hydrate form of Tivozanib (HY-10977). Tivozanib hydrate is a selective, orally active inhibitor for vascular endothelial growth factor receptor (VEGFR)-1, 2 3, with IC₅₀s of 30, 6.5 and 15 nM, respectively. Tivozanib hydrate exhibits antitumor efficacy ^[1].

Pazopanib Hydrochloride 15+ Cited Publications GW786034 Hydrochloride	PDGFR VEGFR FGFR c-Kit c-Fms Autophagy	Cancer
Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with an IC₅₀ of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

TAK-593 1 Publications Verification	PDGFR VEGFR	Cancer
TAK-593 is a potent *VEGFR* and PDGFR family inhibitor with IC₅₀s of 3.2, 0.95, 1.1, 4.3 and 13 nM for VEGFR1, VEGFR2, VEGFR3, PDFGRα and PDFGRβ, respectively.

BMS-605541	VEGFR PDGFR	Cancer
BMS-605541 is a selective and orally active inhibitor of *VEGFR-2* kinase with an IC₅₀ value of 23 nM and K_i value of 49 nM. BMS-605541 inhibits the activity of *Flk-1, VEGFR-1* and PDGFR-β with IC₅₀ values of 40 nM, 400 nM and 200 nM, respectively. BMS-605541 can be used for cancer research ^[1].

Pazopanib 15+ Cited Publications GW786034	VEGFR c-Kit PDGFR Autophagy FGFR	Cancer
Pazopanib (GW786034) is a novel multi-target inhibitor of *VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms* with IC₅₀s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

Necroptosis-IN-4	Necroptosis RIP kinase	Inflammation/Immunology
Necroptosis-IN-4, a potent necroptosis inhibitor, is a RIP kinase 1 (RIPK1) inhibitor. Necroptosis-IN-4 has no inhibitory activity against RIPK3 and weak inhibitory activity against VEGFR1/2 and PDGFR-α ^[1].

CEP-11981 tosylate ESK981 tosylate; BOL 303213X tosylate	VEGFR FGFR	Others Cancer
CEP-11981 (tosylate) (ESK981 (tosylate), BOL 303213X (tosylate)) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, *VEGFR1-3* and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects ^[1].

T-1840383	c-Met/HGFR VEGFR	Cancer
T-1840383 is a potent, ATP-competitive inhibitor of *c-Met/VEGFR-2, with the IC₅₀s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2* and *VEGFR3*, respectively ^[1].

Regorafenib Hydrochloride Maximum Cited Publications 59 Publications Verification BAY 73-4506 hydrochloride	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib Hydrochloride (BAY 73-4506 hydrochloride) is a multi-target inhibitor for *VEGFR1/2/3, PDGFRβ, Kit, RET* and *Raf-1* with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively ^[1].

Sulfatinib (Standard)	FGFR VEGFR	Cancer
Sulfatinib (Standard) is the analytical standard of Sulfatinib. This product is intended for research and analytical applications. Sulfatinib (Surufatinib) is a potent and highly selective tyrosine kinase inhibitor against *VEGFR1/2/3, FGFR1* and *CSF1R* with IC₅₀s of in a range of 1 to 24 nM.

O-Demethyl Lenvatinib	Drug Metabolite	Cancer
O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities ^[1] .

CEP-11981 ESK981; BOL 303213X	VEGFR FGFR	Cancer
CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, *VEGFR1-3* and *FGFR1*, and has potential anti-tumor and anti-angiogenic effects ^[1].

Lucitanib 5+ Cited Publications E-3810	VEGFR FGFR	Cancer
Lucitanib (E-3810) is a novel dual inhibitor of *VEGFR* and FGFR, potently and selectively inhibits *VEGFR1, VEGFR2, VEGFR3, FGFR1* and FGFR2 with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively ^[1] .

O-Demethyl Lenvatinib hydrochloride	Drug Metabolite	Cancer
O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities ^[1] .

Lucitanib dihydrochloride	VEGFR FGFR	Cancer
Lucitanib (E-3810) dihydrochloride is a novel dual inhibitor of *VEGFR* and FGFR, potently and selectively inhibits *VEGFR1, VEGFR2, VEGFR3, FGFR1* and FGFR2 with IC₅₀s of 7 nM, 25 nM, 10 nM, 17.5 nM, and 82.5 nM, respectively ^[1] .

Sitravatinib 3 Publications Verification MGCD516; MG-516	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively ^[1]. Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Sitravatinib malate MGCD516 malate; MG-516 malate	VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor	Inflammation/Immunology Cancer
Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC₅₀s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively ^[1]. Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .

Lenvatinib mesylate (Standard)	VEGFR FGFR PDGFR RET c-Kit	Cancer
Lenvatinib (mesylate) (Standard) is the analytical standard of Lenvatinib (mesylate). This product is intended for research and analytical applications. Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

Lenvatinib (Standard)	VEGFR FGFR PDGFR c-Kit RET	Cancer
Lenvatinib (Standard) is the analytical standard of Lenvatinib. This product is intended for research and analytical applications. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

Axitinib (Standard)	VEGFR PDGFR	Cancer
Axitinib (Standard) is the analytical standard of Axitinib. This product is intended for research and analytical applications. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 0.1, 0.2, 0.1-0.3, 1.6 nM for *VEGFR1, VEGFR2, VEGFR3* and PDGFRβ, respectively.

Regorafénib N-oxyde (M2)	Drug Metabolite PDGFR	Cancer
Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC₅₀s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

Cat. No.	Product Name	Target	Research Area

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P5527F

FAM-CSKtide	Peptides	Others
FAM-CSKtide is a biological active peptide. (This is a FAM labeled peptide substrate (Abs/Em = 494/521 nm) for C-terminal Src kinase (Csk) and many other kinases such as Axl, cKit, ERBB4, Fes, Flt3, IGF-1 R, MET, MUSK, PYK2, Ret, TIE2, TrkA, VEGF-R1 and VEGF-R2.)

Cat. No.	Product Name	Target	Research Area

HY-P99364

Icrucumab Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1	VEGFR	Cancer
Icrucumab (Anti-VEGFR1/FLT1 Reference Antibody; IMC-18F1) is a human *Anti-VEGFR-1* IgG1 monoclonal antibody. Icrucumab has the potential for the research of advanced solid tumors ^[1].

HY-108801

Aflibercept VEGF Trap; VEGF-TRAPR1R2; VEGF-trapR1	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF* signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease ^[1] .

HY-108801A

*Aflibercept (VEGF* Trap)**	VEGFR	Cardiovascular Disease Metabolic Disease Cancer
Aflibercept (VEGF Trap) is a soluble decoy *VEGFR* constructed by fusing the Ig domains of *VEGFR1 and VEGFR2 with the Fc region of human IgG1. Aflibercept inhibits VEGF* signaling by reducing VEGF-regulated processes. Aflibercept can be used for thr research of age-related macular degeneration (AMD) and cardiovascular disease ^[1] .

HY-P990541

*Anti-VEGFR1/FLT1 Antibody*	Inhibitory Antibodies	Inflammation/Immunology
Anti-VEGFR1/FLT1 Antibody is a CHO-expressed humanized antibody that targets *VEGFR1/FLT1. Anti-VEGFR1/FLT1 Antibody contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR1*/FLT1 Antibody can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990088

Sotiburafusp alfa	VEGFR PD-1/PD-L1	Cardiovascular Disease
Sotiburafusp alfa is a bispecific fusion protein, which is a humanized *VEGFR-1* extracellular domain fragment (129-228, 1-100 in the current sequence) fused via the peptide linker ¹⁰¹GGSGGSGGSGGSGGS ¹¹⁵ to the N-terminus of the heavy chain (116-564) of a humanized IgG1-kappa anti-human *PD-L1* heavy chain variant L352>A, L353>A. Sotiburafusp alfa is also an angiogenesis inhibitor ^[1].

Recombinant Proteins Recommended:

VEGFR-1

Species:	Human (6) Rat (1) Mouse (1)
Tag:	His (6) Avi (2) Fc (2)
Source:	HEK293 (8)

Cat. No.	Compare	Product Name	Species	Source

HY-P73552

	VEGFR-1 Protein, Rat (HEK293, His) Vascular endothelial growth factor receptor 1; FLT; FLT1; FRT; VEGFR-1	Rat	HEK293
	VEGFR-1 protein is a tyrosine protein kinase receptor for VEGFA, VEGFB, and PGF and is critical for embryonic vasculature development, angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer invasion. It actively regulates postnatal retinal vitreous vascular degeneration and may act as a negative regulator of embryonic angiogenesis. VEGFR-1 Protein, Rat (HEK293, His) is the recombinant rat-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag. The total length of VEGFR-1 Protein, Rat (HEK293, His) is 736 a.a., with molecular weight of ~110-130 kDa.

HY-P73553

	VEGFR-1 Protein, Mouse (HEK293, His) Vascular endothelial growth factor receptor 1; FLT; FLT1; FRT; VEGFR-1	Mouse	HEK293
	The VEGFR-1 protein is a key tyrosine protein kinase receptor. VEGFR-1 Protein, Mouse (HEK293, His) is the recombinant mouse-derived VEGFR-1 protein, expressed by HEK293 , with C-His, C-10*His labeled tag. The total length of VEGFR-1 Protein, Mouse (HEK293, His) is 737 a.a., with molecular weight of ~130 kDa.

HY-P73065

	VEGFR-1 Protein, Human (328a.a, HEK293, His) Vascular endothelial growth factor receptor 1; FLT; FLT1; FRT; VEGFR-1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (328a.a, HEK293, His) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78230

	VEGFR-1 Protein, Human (Biotinylated, HEK293, His-Avi) FLT; FLT1; Flt-1; FRT; VEGF R1; VEGFR1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.

HY-P73064

	VEGFR-1 Protein, Human (328a.a, HEK293, Fc) Vascular endothelial growth factor receptor 1; FLT; FLT1; FRT; VEGFR-1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (328a.a, HEK293, Fc) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-hFc labeled tag.

HY-P73554

	VEGFR-1 Protein, Human (756a.a, HEK293, His) Vascular endothelial growth factor receptor 1; FLT; FLT1; FRT; VEGFR-1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (756a.a, HEK293, His) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His labeled tag.

HY-P78537

	VEGFR-1 Protein, Human (HEK293, His-Avi) FLT; FLT1; Flt-1; FRT; VEGF R1; VEGFR1	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (HEK293, His-Avi) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-His, C-Avi labeled tag.

HY-P70636

	VEGFR-1 Protein, Human (730a.a, HEK293, Fc) Vascular endothelial growth factor receptor 1; VEGFR-1; Fms-like tyrosine kinase 1; FLT-1; Tyrosine-protein kinase FRT; Tyrosine-protein kinase receptor FLT; Vascular permeability factor receptor	Human	HEK293
	The VEGFR-1 protein is a tyrosine protein kinase that acts as a cell surface receptor for VEGFA, VEGFB, and PGF. It plays a crucial role in embryonic vasculature development, regulation of angiogenesis, cell survival, migration, macrophage function, chemotaxis, and cancer cell invasion. VEGFR-1 Protein, Human (730a.a, HEK293, Fc) is the recombinant human-derived VEGFR-1 protein, expressed by HEK293 , with C-hFc labeled tag.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10981S

Lenvatinib-d4
Lenvatinib-d₄ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-10208S

Pazopanib-d6
Pazopanib-d₆ is the deuterium labeled Pazopanib. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.

HY-10065S

Axitinib-13C,d3
Axitinib- ¹³C,d₃ is a ¹³C-labeled and deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.

HY-10065S1

Axitinib-d3
Axitinib-d₃ (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively[1].

HY-W758126

(R)-Brivanib alaninate-d4
(R)-Brivanib alaninate-d₄ is the deuterium-labeled Brivanib (alaninate) (HY-10336). Brivanib alaninate (BMS-582664) is an ATP-competitive inhibitor against *VEGFR2* with an IC₅₀ of 25 nM; has moderate potency against VEGFR-1 and FGFR-1, but more than 240-fold against PDGFRβ ^[1].

HY-10981S1

Lenvatinib-d5
Lenvatinib-d₅ is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].

HY-10981S2

Lenvatinib-15N,d4
Lenvatinib- ¹⁵N,d₄ is ¹⁵N and deuterated labeled Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits *VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET*, shows potent antitumor activities ^[1] .

HY-50905S

Dovitinib-d8
Dovitinib-d₈ is the deuterium labeled Dovitinib. Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively[1][2].

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

HY-10208S1

Pazopanib-13C,d3
Pazopanib- ¹³C,d₃ is the deuterium and ¹³C labeled Pazopanib[1]. Pazopanib (GW786034) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with IC50s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-12009S

Pazopanib-13C,d3 hydrochloride
Pazopanib- ¹³C,d₃ (hydrochloride) is the deuterium and ¹³C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3].

HY-50904S

Nintedanib-d3
Nintedanib-d₃ is the deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-10230S

Midostaurin-d5
Midostaurin-d₅ is a deuterium labeled Midostaurin. Midostaurin is a multi-targeted protein kinase inhibitor which inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50s ranging from 22-500 nM[1].

HY-50904S2

Nintedanib-d8
Nintedanib-d₈ is deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-50904S1

Nintedanib-13C,d3
Nintedanib- ¹³C,d₃ is the ¹³C- and deuterium labeled Nintedanib. Nintedanib (BIBF 1120) is a potent triple angiokinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β with IC50s of 34 nM/13 nM/13 nM, 69 nM/37 nM/108 nM and 59 nM/65 nM, respectively.

HY-I0678S1

Regorafénib N-oxyde (M2)-13C,d3
Regorafénib N-oxyde (M2)- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively.

HY-I0678S

Regorafénib N-oxyde-d3 (M2)
Regorafénib N-oxyde-d₃(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].

HY-10873S

N-Desethyl Sunitinib-d5
N-Desethyl Sunitinib-d₅ is the deuterium labeled N-Desethyl Sunitinib. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive VEGFR, PDGFRβ and KIT inhibitor with Ki values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively[1].

HY-10873S2

N-Desethyl Sunitinib-d5 hydrochloride
N-Desethyl Sunitinib-d5 (hydrochloride) is a deuterated labeled N-Desethyl Sunitinib ^[1]. N-Desethyl Sunitinib (SU-12662) is a metabolite of sunitinib. Sunitinib is a potent, ATP-competitive *VEGFR, PDGFRβ* and KIT inhibitor with K_i values of 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFRβ and KIT, respectively .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80928

	VEGF Receptor 1 Antibody VEGFR-1; VEGF Receptor 1; FLT-1; FLT; FRT; VEGFR1; Fms-like tyrosine kinase 1; Tyrosine-protein kinase FRT	WB, IHC-P, IP	Human, Mouse, Rat
	VEGF Receptor 1 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 151 kDa, targeting to VEGF Receptor 1. It can be used for WB,IHC-P,IP assays with tag free, in the background of Human, Mouse, Rat.